- Universal Health reports a first-quarter adjusted EPS of $3.70, beating the estimated $3.14 and last year’s $2.34.
- The company’s net revenue rose to $3.84 billion, up 11% from last year, surpassing the $3.77 billion estimate.
- Adjusted admissions for the same facility acute care increased by 4.5%.
- Acute Care Hospital Services on a same-facility basis saw net revenue of $2.11 billion, a 12% increase from the previous year.
- The Behavioral Health Care Services’ same facility basis net revenue increased by 11% to reach $1.62 billion.
- Adjusted net income went up by 51%, totaling $253.1 million, beating the estimated $214.4 million.
- The company’s stocks are rated at 8 buys, 10 holds and 1 sell, suggesting a somewhat mixed opinion among investors.
A look at Universal Health Services B Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts from Smartkarma have evaluated Universal Health Services B using their Smart Scores system, which rates various aspects of the company’s outlook. Universal Health Services B has received a favorable score of 4 for Momentum, indicating strong positive market momentum. This suggests that the company may be experiencing an upward trend in its stock performance.
In addition, Universal Health Services B has also scored well in Value and Growth with scores of 3 for both factors. This signifies that the company’s stock may be undervalued and has the potential for future growth. Despite lower scores in Dividend and Resilience at 2 each, the overall outlook for Universal Health Services B appears promising for long-term investment opportunities.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
